PD16-04 ALTERATIONS OF HEMATOGENESIS AND BONE MINERAL DENSITY AFTER DUTASTERIDE TREATMENT IN AGED PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA

You have accessJournal of UrologyBenign Prostatic Hyperplasia: Medical & Non-Surgical Therapy1 Apr 2015PD16-04 ALTERATIONS OF HEMATOGENESIS AND BONE MINERAL DENSITY AFTER DUTASTERIDE TREATMENT IN AGED PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA Kenichi Mori, Shinsuke Mizoguchi, Yasuhiro Sumino, Fuminori Sato, Naoki Yoshimura, and Hiromitsu Mimata Kenichi MoriKenichi Mori More articles by this author , Shinsuke MizoguchiShinsuke Mizoguchi More articles by this author , Yasuhiro SuminoYasuhiro Sumino More articles by this author , Fuminori SatoFuminori Sato More articles by this author , Naoki YoshimuraNaoki Yoshimura More articles by this author , and Hiromitsu MimataHiromitsu Mimata More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2015.02.1288AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Testosterone maintains bone mineral density (BMD) and hematogenesis in men. Therefore, hypogonadism can decrease BMD and hematogenesis. Because most patients with benign prostatic hyperplasia (BPH) are aged persons, there is a possibility of hypogonadism in aged BPH patients. Dutasteride administration for BPH can increase blood levels of testosterone; however, it is not known whether BMD and hematogenesis are altered after dutasteride administration. Therefore, the effects of dutasteride on BMD and hematogenesis in patients with BPH were investigated. METHODS Sixty-four patients with BPH, who were taking 0.5 mg dutasteride daily for a year, were investigated retrospectively. All patients were concomitantly taking alpha-blockers, and two patients were treated with anticholinergic drugs. BMD, prostate volume (PV) and blood hemoglobin (Hb), hematocrit (Ht), total cholesterol (T-CHOL), HDL cholesterol (HDL), and free testosterone (FT) levels were examined before and after dutasteride administration. BMD was investigated using dual-energy X-ray absorptiometry. The questionnaires such as International prostatic symptom score (IPSS), Overactive Bladder Symptom score (OABSS) and Aging Male Symptoms rating scale (AMS) were also evaluated. RESULTS Median age and FT levels prior to the treatment were 77 years old and 5.4 pg/mL (ranged from 9.1 to 3.9 pg/mL), respectively. Post-treatment PV, IPSS and OABSS were significantly decreased compared with those of pre-treatment (P<0.05). Post-treatment Hb and Ht levels were significantly increased compared with those of pre-treatment (P<0.05). Post-treatment BMD was also significantly increased compared with that of pre-treatment (P<0.05). Furthermore, T-CHOL levels were significantly decreased after a year, whereas HDL levels were significantly increased compared with pre-treatment values (P<0.05). Post-treatment FT levels (mean: 6.4 pg/mL) were significantly increased, and AMS was significantly decreased compared with pre-treatment values (P<0.05). CONCLUSIONS In this study, most patients had hypogonadism, evidenced by the mean baseline FT level at 5.4 pg/mL. Thus, dutasteride administration might be effective for the treatment of BPH patients with hypogonadism because dutasteride administration could increase FT blood levels, which leads to improve not only hematogenesis, but also and BMD. Furthermore, improved daily living activity evidenced by increased AMS can also contribute to the improvement of lipid metabolism and BMD. © 2015 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 193Issue 4SApril 2015Page: e331 Advertisement Copyright & Permissions© 2015 by American Urological Association Education and Research, Inc.MetricsAuthor Information Kenichi Mori More articles by this author Shinsuke Mizoguchi More articles by this author Yasuhiro Sumino More articles by this author Fuminori Sato More articles by this author Naoki Yoshimura More articles by this author Hiromitsu Mimata More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...